Tiziana Life Sciences PLC Appointment of VP of Regulatory Affairs (5165C)
June 21 2021 - 2:08AM
UK Regulatory
TIDMTILS
RNS Number : 5165C
Tiziana Life Sciences PLC
21 June 2021
Tiziana Appoints Dr. Kevin Schutz as Vice-President of
Regulatory Affairs
NEW YORK & LONDON, June 21, 2021 - Tiziana Life Sciences plc
(NASDAQ: TLSA, LSE: TILS ), a biotechnology company focused on
innovative therapeutics for oncology, neurology, inflammation and
infectious diseases, is pleased to announce the appointment of Dr.
Kevin Schutz, PharmD, as Vice-President of Regulatory Affairs. Dr.
Schutz will lead regulatory interactions related to clinical
studies in the United States, Europe and Asian countries.
Dr. Schutz has over 19 years of pharmaceutical industry
experience including 14 years of Regulatory Affairs experience. He
has focused on disease indications with high unmet medical needs,
in Neurology (including multiple sclerosis), Pulmonology (including
infectious disease), and other potential disease indications, which
the Company is currently developing products for or is planning to
pursue. Specifically, Foralumab (an intranasally delivered, next
generation, fully human anti-CD3 monoclonal antibody) for Secondary
Progressive Multiple Sclerosis (SPMS) and COVID-19 with Pulmonary
Inflammation as lead indications.
"Dr. Schutz brings extensive hands-on experience working with
regulatory agencies including the FDA (USA), EMA (Europe), and PMDA
(Japan), among others. His background will greatly strengthen
Tiziana's global development capabilities in regions where the
Company is actively pursuing clinical development. We are pleased
to have him on our team to lead this important role in global
development of our pipeline" commented Dr. Neil Graham, Chief
Medical Officer of Tiziana Life Sciences
"I am excited to join the Tiziana team to further the
development of products which aim to help patients manage diseases
with an unmet medical need. Tiziana's lead pipeline candidate,
Foralumab, is promising with multiple potential indications in
multiple sclerosis and pulmonary diseases and I look forward to
contributing to its development" said Dr. Schutz.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS ) is a UK
biotechnology company that focuses on the discovery and development
of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being
developed in oncology), the Company is also developing Foralumab in
COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the
only second generation fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as nonalcoholic steatohepatitis (NASH),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammatory pulmonary diseases.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc. 407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFBMFTMTMTMRB
(END) Dow Jones Newswires
June 21, 2021 02:08 ET (06:08 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jul 2023 to Jul 2024